Skip to main content
SpringerLink
Log in

Angststörungen

Klinische Psychopharmakotherapie

  • Chapter
Book cover Handbuch der psychiatrischen Pharmakotherapie

Zusammenfassung

Pathologisches Angsterleben ist häufig Bestandteil zahlreicher psychiatrischer und somatischer Erkrankungen und beeinflusst oft deren Verlauf, Th erapie und Prognose. Syndromal werden durch die aktuellen Klassifikationssysteme psychiatrischer Erkrankungen (ICD-10: 10. Revision der International Classification of Diseases der Weltgesundheitsorganisation bzw. DSM-IV: 4. Revision des Diagnostic and Statistical Manual of Mental Disorders der American Psychiatric Association) fünf bzw. sieben Angststörungen unterschieden, die sich hauptsächlich durch deren jeweiligen Angstverlauf, das Vorhandensein bzw. Fehlen eines konkreten anxiogenen Stimulus sowie epidemiologische Besonderheiten voneinander abgrenzen. Obwohl die aktuellen Versionen beider Systeme in ihren psychopathologischen Defi- nitionen der einzelnen Angststörungen weitgehend übereinstimmen, subsummiert an dieser Stelle das DSM-IV im Gegensatz zur ICD-10 auch die Zwangsstörung sowie die posttraumatische Belastungsstörung (PTBS).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Achim AM, Maziade M, Raymond E et al (2011) How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association. Schizophr Bull 37(4): 811–821

    Article  PubMed Central  PubMed  Google Scholar 

  • Aliyev NA, Aliyev ZN (2008) Valproate (depakine-chrono) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: randomized, double-blind placebo-controlled study. Eur Psychiatry 23: 109–114

    Article  PubMed  Google Scholar 

  • Allgulander C (2010) Novel approaches to treatment of generalized anxiety disorder. Curr Opin Psychiatry 23: 37–42

    Article  PubMed  Google Scholar 

  • Altamura AC, Serati M, Buoli M, Dell’osso B (2011) Augmentative quetiapine in partial/nonresponders with generalized anxiety disorder: a randomized, placebo-controlled study. Int Clin Psychopharmacol 26(4): 201–205

    Article  PubMed  Google Scholar 

  • Bakker A, van Balkom AJ, Spinhoven P (2002) SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis. Acta Psychiatr Scand 106: 163–167

    Article  CAS  PubMed  Google Scholar 

  • Bandelow B, Rüther E (2004) Treatment-resistant panic disorder. CNS Spectrums 9: 725–739

    PubMed  Google Scholar 

  • Bandelow B, Zohar J, Hollander E et al, WFSBP Task Force on Treatment Guidelines for Anxiety Obsessive-Compulsive Post-Traumatic Stress Disorders (2008) World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive- Compulsive and Post-Traumatic Stress Disorders – First Revision. World J Biol Psychiatry 9: 248–312

    Article  PubMed  Google Scholar 

  • Bandelow B, Chouinard G, Bobes J et al (2010) Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placeboand active-controlled study. Int J Neuropsychopharmacol 13: 305–320

    Article  CAS  PubMed  Google Scholar 

  • Barnett SD, Kramer ML, Casat CD et al (2002) Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol 16: 365–368

    Article  CAS  PubMed  Google Scholar 

  • Benjamin J, Ben-Zion IZ, Karbofsky E, Dannon P (2000) Double-blind placebo- controlled pilot study of paroxetine for specific phobia. Psychopharmacology 149: 194–196

    Article  CAS  PubMed  Google Scholar 

  • Bose A, Korotzer A, Gommoll C, Li D (2008) Randomized placebo-controlled trial of escitalopram and venlafaxine xr in the treatment of generalized anxiety disorder. Depr Anxiety 25: 854–861

    Article  Google Scholar 

  • Choy Y, Fyer AJ, Lipsitz JD (2007) Treatment of specific phobia in adults. Clin Psychol Rev 27: 266–286

    Article  PubMed  Google Scholar 

  • El-Malakh RS, Hollifield M (2008) Comorbid anxiety in bipolar disorder alters treatment and prognosis. Psychiatr Quart 79: 139–150

    Article  Google Scholar 

  • Fava, GA, Porcelli P, Rafanelli C et al (2010) The spectrum of anxiety disorders in the medical ill. J Clin Psychiatry 71: 910–914

    Article  PubMed  Google Scholar 

  • Ferreri M, Hantouche EG, Billardon M (1994) Value of hydroxyzine in generalized anxiety disorder: controlled double-blind study versus placebo. Encéphale 20: 785–791

    CAS  PubMed  Google Scholar 

  • Furmark M, Appel L, Michelgård A et al (2005) Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry 58: 132–142

    Article  CAS  PubMed  Google Scholar 

  • Goddard AW, Brounette T, Almai A et al (2001) Earley coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry 58: 681–686

    Article  CAS  PubMed  Google Scholar 

  • Hawgood J, De Leo D (2008) Anxiety disorders and suicidal behaviour: an up-date. Curr Opin Psychiatry 21: 51–64

    Article  PubMed  Google Scholar 

  • Hirschmann S, Dannon PN, Iancu I et al (2000) Pindolol augmentation in patients with treatment-resistant panic disorder: a double-blind, placebocontrolled trial. J Clin Psychopharmacol 20: 556–559

    Article  CAS  PubMed  Google Scholar 

  • Hofmann SG, Meuret AE, Smits JAJ et al (2006) Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry 63: 298–304

    Article  CAS  PubMed  Google Scholar 

  • Hofmann SG, Sawyer AT, Korte KJ (2009) Is it beneficial to add pharmacothetherapy to cognitive-behavioral therapy when treating anxiety disorders? A meta-analytic review. Int J Cogn Ther 2: 160–175

    Article  PubMed Central  PubMed  Google Scholar 

  • Hunot V, Churchill R, Teixeira V, Silva de Lima M (2010) Psychological therapies for generalised anxiety disorder (review). Cochrane Database Syst Rev 4: CD001848

    Google Scholar 

  • Katzman MA, Brawman-Mintzer O, Reyes EB et al (2011) Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial. Int Clin Psychopharmacol 26(1):11–24

    Article  PubMed  Google Scholar 

  • Kessler RC, Berglund P, Demler O et al (2005a) Lifetime prevalence and ageof- onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62: 593–602

    Article  PubMed  Google Scholar 

  • Kessler RC, Chiu WT, Demler O et al (2005b) Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62: 617–627

    Article  PubMed Central  PubMed  Google Scholar 

  • Klein DF (1987) Anxiety reconceptualized. Gleaning from pharmacological dissection – early experience with clomipramine and anxiety. Mod Probl Pharmacopsychiatry 22: 1–35

    CAS  PubMed  Google Scholar 

  • Lader M, Scotto JC (1998) A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder. Psychopharmacology 139: 402–406

    Article  CAS  PubMed  Google Scholar 

  • Liebowitz MR, Gelenberg AJ, Munjack D (2005) Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry 62 : 190–198

    Article  CAS  PubMed  Google Scholar 

  • Llorca PM, Spadone C, Sol O et al (2002) Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder : a 3-month double-blind study. J Clin Psychiatry: 63: 1020–1027

    Article  CAS  PubMed  Google Scholar 

  • Lum M, Fontaine R, Elie R, Ontiveros A (1990) Divalproex sodium’s antipanic effect in panic disorder: a placebo-controlled study. Biol Psychiatry 27: 41A-179A

    Google Scholar 

  • Mann K, Hintz T, Jung M (2004) Does psychiatric comorbidity in alcohol-dependent patients affect treatment outcome? Eur Arch Psychiatry Clin Neurosci 254: 172–181

    Article  PubMed  Google Scholar 

  • Marks IM, Gelder MG (1966) Different ages of onset in varietes of phobias. Am J Psychiatry 123: 218–221

    Article  CAS  PubMed  Google Scholar 

  • Mendels J, Krajewski TF, Huffer V et al (1986) Effective short-term treatment of generalized anxiety disorder with trifluoperazine. J Clin Psychiatry 47: 170–174

    CAS  PubMed  Google Scholar 

  • Mitte K (2005) A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and withoutout agoraphobia. J Affect Disord 88: 27–45

    Article  PubMed  Google Scholar 

  • Merom D, Phongsavan P, Wagner R et al (2007) Promoting walking as an adjunct intervention to group cognitive therapy for anxiety disorders: a pilot group randomized trial. J Anxiety Disord 22: 959–968

    Article  PubMed  Google Scholar 

  • Montgomery SA, Tobias, Zornberg GL et al (2006) Efficiacy and safety of pregabalin in the treatment generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 67: 771–782

    Article  CAS  PubMed  Google Scholar 

  • Möller HJ, Volz HP, Reimann IW, Stoll KP (2001) Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. J Clin Psychopharmacol 21: 59–65

    Article  PubMed  Google Scholar 

  • Muehlbacher M, Nickel MK, Nickel C et al (2005) Mirtazapine treatment of social phobia in women. A randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 25: 580–583

    Article  CAS  PubMed  Google Scholar 

  • Mörtberg E, Clark DM, Sundin O, Aberg WA (2007) Intensive group cognitive treatment and individual cognitive therapy vs treatment as usual in social phobia: a randomized controlled trial. Acta Psychiatr Scand 115: 142–152

    Article  PubMed  Google Scholar 

  • Mula M, Pini S, Cassano GB (2007) The role of anticonvulsive drugs in anxiety disorders: a critical review of the evidence. J Clin Psychopharmacol 27: 263–272

    Article  CAS  PubMed  Google Scholar 

  • Öst LG, Thulin U, Ramnerö J (2004) Cognitive behavior therapy vs. exposure in vivo in the treatment of panic disorder with agoraphobia. Behav Res Ther 42: 1105–1127

    Article  PubMed  Google Scholar 

  • Olantuji BO, Cisler JM, Tolin DF (2007) Quality of life in the anxiety disorders: a meta-analytic review. Clin Psychol Rev 27: 572–581

    Article  Google Scholar 

  • Otto MW, Tolin DF, Simon NM et al (2010) Efficacy of D-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry 67: 365–370

    Article  CAS  PubMed  Google Scholar 

  • Pande AC, Davidson J, Jefferson JW et al (1999) Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 19: 341–348

    Article  CAS  PubMed  Google Scholar 

  • Pande AC, Pollack MH, Crockatt J et al (2000) Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 20: 467–471

    Article  CAS  PubMed  Google Scholar 

  • Pande AC, Feltner DE, Jefferson JW et al (2004) Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol 24:141–149

    Article  CAS  PubMed  Google Scholar 

  • Pandina GJ, Canuso CM, Turkoz I et al (2007) Adjunctive risperidone in the treatment of generalized anxiety disorder: a double-blind, prospective, placebo-controlled, randomized trial. Psychopharmacol Bull 40: 41–57

    PubMed  Google Scholar 

  • Pollack MH, Otto MW, Tesar GE et al (1993) Long-term outcome after acute treatment with alprazolam and clonazepam for panic disorder. Psychopharmacology 194: 233–242

    Article  Google Scholar 

  • Pollack MH, Simon NM, Zalta AK et al (2006) Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry 59: 211–215

    Article  CAS  PubMed  Google Scholar 

  • Pollack M, Mangano R, Entsuah R et al (2007) A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology 194: 233–242

    Article  CAS  PubMed  Google Scholar 

  • Ribeiro L, Busnello JV, Kauer-Sant’Anna M et al (2001) Mirtazapine versus fluoxetine in the treatment of panic disorder. Braz J Med Biol Res 34: 1303–1307

    Article  CAS  PubMed  Google Scholar 

  • Rupprecht R, Rammes G, Eser D et al (2009) Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. Science 325: 490–493

    Article  CAS  PubMed  Google Scholar 

  • Siegmund A, Golfels F, Finck C et al (2011) D-Cycloserine does not improve but might slightly speed up the outcome of in-vivo exposure therapy in patients with severe agoraphobia and panic disorder in a randomized double blind clinical trial. J Psychiatr Res 45: 1–6

    Article  Google Scholar 

  • Stein DJ, Ahokas A, Fabiano A (2007) Agomelatine in generalized anxiety disorder: a randomized, placebo-controlled, study. Anxiety Disord P4a: S509-S510

    Google Scholar 

  • Strand M, Hetta J, Rosen A et al (1990) A double-blind, controlled trial in primary care patients with generalized anxiety: a comparison between buspirone and oxazepam. J Clin Psychiatry 51(Suppl): 40–45

    PubMed  Google Scholar 

  • Ströhle A, Höfler M, Pfister H et al (2007) Physical activity and prevalence and incidence of mental disorders in adolescents and young adults. Psychol Med 37: 1657–1666

    PubMed  Google Scholar 

  • Swinbourne JM, Toyz SW (2007) The co-morbidity of eating disorders and anxiety disorders: a review. Eur Eat Disord Rev 15: 253–274

    Article  PubMed  Google Scholar 

  • Uhlenhuth EH, Warner TD, Matuzas W (2002) Interactive model of therapeutic response in panic disorder: moclobemide, a case in point. J Clin Psychopharmacol 22: 275–284

    Article  CAS  PubMed  Google Scholar 

  • Versiani M, Nardi AE, Mundim FD et al (1992) Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. Br J Psychiatry 161: 353–36

    Article  CAS  PubMed  Google Scholar 

  • Versiani M, Cassano G, Perugi G et al (2002) Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. J Clin Psychiatry 63: 31–37

    Article  CAS  PubMed  Google Scholar 

  • Wise CD, Berger BD, Stein L (1970) Serotonin: a possible mediator of behavioral suppression induced by anxiety. Dis Nerv Syst 31(Suppl): 34–37

    PubMed  Google Scholar 

  • Yonkers KA, Warshaw MG, Massion AO, Keller MB (1996) Phenomenology and course of generalized anxiety disorder. Br J Psychiatry 168: 308–313

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Psychiatrie und Psychotherapie, Charité Campus Mitte, Charitéplatz 1, 10117, Berlin

    Dr. Jens Plag

  2. Klinik für Psychiatrie und Psychotherapie, Charité Campus Mitte, Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin

    PD Dr. Andreas Ströhle

Authors
  1. Dr. Jens Plag
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. PD Dr. Andreas Ströhle
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Psychiatrie, Psychotherapie und Psychosomatik, Pauwelsstr. 30, 52074, Aachen

    Gerhard Gründer

  2. Luisenstr. 19, 55124, Mainz

    Otto Benkert

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Plag, J., Ströhle, A. (2012). Angststörungen. In: Gründer, G., Benkert, O. (eds) Handbuch der psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-19844-1_78

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-19844-1_78

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-19843-4

  • Online ISBN: 978-3-642-19844-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation